Unknown

Dataset Information

0

Selection bias, investment decisions and treatment effect distributions.


ABSTRACT: When making decisions regarding the investment and design for a Phase 3 programme in the development of a new drug, the results from preceding Phase 2 trials are an important source of information. However, only projects in which the Phase 2 results show promising treatment effects will typically be considered for a Phase 3 investment decision. This implies that, for those projects where Phase 3 is pursued, the underlying Phase 2 estimates are subject to selection bias. We will in this article investigate the nature of this selection bias based on a selection of distributions for the treatment effect. We illustrate some properties of Bayesian estimates, providing shrinkage of the Phase 2 estimate to counteract the selection bias. We further give some empirical guidance regarding the choice of prior distribution and comment on the consequences for decision-making in investment and planning for Phase 3 programmes.

SUBMITTER: Wiklund SJ 

PROVIDER: S-EPMC9290610 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8255958 | biostudies-literature
| S-EPMC5727086 | biostudies-other
| S-EPMC4693420 | biostudies-literature
| S-EPMC4280402 | biostudies-literature
| S-EPMC5802450 | biostudies-literature
| S-EPMC6121851 | biostudies-literature
| S-EPMC3885520 | biostudies-literature
| S-EPMC8027662 | biostudies-literature
| S-EPMC5193423 | biostudies-literature
| S-EPMC5121093 | biostudies-literature